Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound ginkgo biloba extract is a botanical combination product, typically formulated as oral tablets, containing *Ginkgo biloba* extract and *Panax notoginseng*. Developed by Hunan Fangsheng Pharmaceutical, it is primarily investigated for the treatment of vascular dementia, particularly the "stasis blocking brain collaterals" syndrome in Traditional Chinese Medicine. The therapeutic effects are derived from active constituents such as ginkgolides, bilobalide, and flavonoids, which function as platelet-activating factor (PAF) receptor antagonists and antioxidants. These actions help to improve cerebral microcirculation, reduce blood viscosity, and provide neuroprotection against ischemic damage. Clinical development has focused on evaluating its efficacy and safety in improving cognitive function and activities of daily living in patients with vascular dementia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound ginkgo biloba extract.